id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326154-01es0zv4	Aggarwal, Gaurav	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019	2020-05-16		.txt	text/plain	2305	127	42	Moreover, a decreased potassium level has also been reported in patients with COVID-19, which can cause electrocardiographic changes like prolonged QT interval and may increase the risk of adverse reactions with pharmacotherapies. The drugs of highest interest to-date include chloroquine/hydroxychloroquine (CQ/HCQ) alone or in combination with azithromycin, remdesivir, lopinavir/ritonavir and interferon alpha-2b 3 . A large meta-analysis of 33 randomized and observational studies found azithromycin use to be associated with higher risk of cardiovascular death but not with all-cause death 19 . If this drug does show therapeutic efficacy in treatment of COVID-19, then ongoing surveillance would be needed to study its potential cardiovascular adverse effects. The patients who have underlying cardiovascular disease or those who develop cardiac dysfunction during infection with COVID-19 are at higher risk of mortality. Though cumulative dose effects impact toxicity, conduction defects, prolongation of QTc interval, cardiomyopathy and ischemic heart disease have been shown to occur with use of hydroxychloroquine, chloroquine, azithromycin, remdesivir, interferon-alpha and lopinavir/ritonavir therapies.	./cache/cord-326154-01es0zv4.txt	./txt/cord-326154-01es0zv4.txt